Rita Nanda, MD, presents results from the I-SPY 2 trial at the ASCO annual meeting showing that adding the checkpoint blocker pembrolizumab (KeytrudaTM) to standard therapy dramatically improved response rates for patients with invasive triple-negative breast cancer.
Finding genetic variations common in black women could improve outcomes and reduce recurrence of breast cancer, according to a new study.
Susan G. Komen, one of the nation’s leading breast cancer organizations, recently awarded the UChicago Comprehensive Cancer Center a three-year, $405,000 grant to establish a graduate training program to study the causes of breast cancer disparities.
Geoffrey Greene, PhD, and team show that when exposed to estrogens and progestins, certain receptor proteins interact with chromosomes and dramatically alter how estrogen receptors interact with the cell’s DNA.
A nurse for almost 40 years, Therese Galvan understands the critical importance of finding the right place to get care and treatment. So when a lump she discovered in her left breast was found to be malignant, she turned to the University of Chicago Medicine Comprehensive Cancer Center at Silver Cross Hospital in New Lenox.
Immunotherapy has become a rapid, remarkable success. Now, the results of a clinical trial by Rita Nanda, MD, becomes the first published report to show its effectiveness against triple-negative breast cancer.
The U.S. Preventive Services Task Force issued its latest guidelines for breast cancer screening, emphasizing individual decision-making on mammograms.
A study by Tara Henderson, MD, MPH, shows that drugs commonly used against leukemia and sarcoma may increase subsequent cancer risk.